"The release demonstrates Everest's end-to-end capabilities across the whole value chain of our mRNA platform," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Off-the-shelf mRNA therapeutic cancer vaccines such as EVM14 can significantly shorten production cycles, improve scalability, and lower manufacturing costs, ultimately benefiting more patients. Through our clinically validated and fully-integrated mRNA platform, we have realized synergies with our 'AI-powered' pipeline to significantly enhanced the efficiency of mRNA vaccine development. This not only provides strong support for the development of EVM14 and other pipeline assets, but also establishes differentiated competitive advantages as we deepen our strategic focus on mRNA-based cancer therapies and in vivo CAR-T programs.